Monday is likely to be rough for Atossa Genetics (ATOS).
The shares fell 49% AH Friday, as the company announced the voluntary recall of the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test.
Although a new premarket application is expected by the end of October, CEO Steven Quay says "the government shutdown makes the timing of [a presubmission] meeting and the subsequent filing impossible to predict."
ATOS did not say when the tests would go on sale again.
Subscribe for full text news in your inbox